AstraZeneca PLC (AZN)vsMeiraGTx Holdings PLC (MGTX)
AZN
AstraZeneca PLC
$169.51
+2.88%
HEALTHCARE · Cap: $263.78B
MGTX
MeiraGTx Holdings PLC
$9.71
-0.46%
HEALTHCARE · Cap: $884.56M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 15338% more annual revenue ($61.37B vs $397.50M). MGTX leads profitability with a 19.9% profit margin vs 17.0%. MGTX trades at a lower P/E of 10.7x. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
MGTX
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.1%
Fair Value
$194.96
Current Price
$169.51
$25.45 discount
Intrinsic value data unavailable for MGTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 37 in profit
Strong operational efficiency at 76.0%
Revenue surging 8609.0% year-over-year
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bull Case : MGTX
The strongest argument for MGTX centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 19.9% and operating margin at 76.0%. Revenue growth of 8609.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : MGTX
The primary concerns for MGTX are EPS Growth, Market Cap, Free Cash Flow.
Key Dynamics to Monitor
AZN profiles as a mature stock while MGTX is a growth play — different risk/reward profiles.
MGTX carries more volatility with a beta of 1.35 — expect wider price swings.
MGTX is growing revenue faster at 8609.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 61/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
MeiraGTx Holdings PLC
HEALTHCARE · BIOTECHNOLOGY · USA
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?